The Medicines Company (MDCO) – Financial and Strategic SWOT Analysis Review

The Medicines Company (MDCO) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
57
Pharmaceuticals and Healthcare
United States

The Medicines Company (MDCO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

The Medicines Company (TMC) is a biopharmaceutical company providing medical solutions for improving health conditions in critical care patients. The product portfolio of the company comprises six marketed products, namely, Angiomax (bivalirudin), Recothrom Thrombin, Cleviprex, Orbactiv, Minocin and Argatroban; and three globally marketed products, namely, Angiomax, Angiox and Recothrom Thrombin. Its pipeline includes seven pipeline products which include five late-stage development products such as cangrelor, oritavancin, Fibrocaps, RPX-602 and IONSYS (fentanyl iontophoretic transdermal system), and two early stage development product such as MDCO-216 and ALN-PCS.

The Medicines Company Key Recent Developments

Feb 18, 2015 The Medicines Company Reports Fourth Quarter and Full Year 2014 Financial Results
Oct 22, 2014 The Medicines Company Reports Third Quarter and First Nine Months 2014 Results
Oct 06, 2014 The Medicines Company Infectious Disease Portfolio Data To Be Presented At ID Week 2014
Aug 27, 2014 The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
The Medicines Company – Key Facts 6
The Medicines Company – Key Employees 7
The Medicines Company – Key Employee Biographies 8
The Medicines Company – Major Products and Services 9
The Medicines Company – Pharmaceutical Pipeline Products Data 10
The Medicines Company, Pipeline Products by Therapy Area 10
The Medicines Company, Pipeline Products by Development Phase 11
The Medicines Company – History 13
The Medicines Company – Company Statement 16
The Medicines Company – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 21
The Medicines Company – Business Description 21
The Medicines Company – Corporate Strategy 23
The Medicines Company – SWOT Analysis 24
SWOT Analysis – Overview 24
The Medicines Company – Strengths 24
Strength – Strong Presence across the Acute Care Products Market 24
Strength – Focused Research and Development Activities 24
Strength – Inorganic Growth: Strategic Acquisitions 24
The Medicines Company – Weaknesses 25
Weakness – Operational Inefficiency 25
Weakness – Customer Concentration 25
Weakness – Dependence on Third Party Manufacturers 25
Weakness – Complete Response Letter 25
The Medicines Company – Opportunities 26
Opportunity – Qualified Infectious Disease Product Designation 26
Opportunity – Demographic Trends 26
Opportunity – Strategic Collaborations and Agreements 26
The Medicines Company – Threats 27
Threat – Competitive Landscape 27
Threat – Government Regulations 27
Threat – Uncertain R&D Outcomes 27
The Medicines Company – Key Competitors 28
Section 3 – Company Financial Ratios 29
Financial Ratios – Capital Market Ratios 29
Financial Ratios – Annual Ratios 30
Performance Chart 32
Financial Performance 32
Financial Ratios – Interim Ratios 33
Financial Ratios – Ratio Charts 34
Section 4 – Company’s Lifesciences Financial Deals and Alliances 35
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 35
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 36
The Medicines Company, Recent Deals Summary 37
Section 5 – Company’s Recent Developments 38
Feb 18, 2015: The Medicines Company Reports Fourth Quarter and Full Year 2014 Financial Results 38
Oct 22, 2014: The Medicines Company Reports Third Quarter and First Nine Months 2014 Results 39
Oct 06, 2014: The Medicines Company Infectious Disease Portfolio Data To Be Presented At ID Week 2014 41
Aug 27, 2014: The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 45
Jul 23, 2014: The Medicines Company Reports Second Quarter and First Half 2014 Results 46
Jun 05, 2014: New antibiotic could provide single-dose option for skin infections 47
Jun 04, 2014: The Medicines Company Presents Seven Hospital Data Analyses at Leading Health Economics and Outcomes Research Conferences 48
Apr 23, 2014: The Medicines Company Reports First Quarter 2014 Financial Results 49
Apr 18, 2014: Pomerantz Law Firm Announces the Filing of a Class Action Against The Medicines Company and Certain Officers 50
Feb 19, 2014: The Medicines Company Reports Fourth Quarter and Full Year 2013 Financial Results 51
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57



List of Tables
The Medicines Company, Key Facts 6
The Medicines Company, Key Employees 7
The Medicines Company, Key Employee Biographies 8
The Medicines Company, Major Products and Services 9
The Medicines Company, Number of Pipeline Products by Therapy Area 10
The Medicines Company, Number of Pipeline Products by Development Stage 11
The Medicines Company, Pipeline Products By Therapy Area and Development Phase 12
The Medicines Company, History 13
The Medicines Company, Other Locations 17
The Medicines Company, Subsidiaries 18
The Medicines Company, Key Competitors 28
The Medicines Company, Ratios based on current share price 29
The Medicines Company, Annual Ratios 30
The Medicines Company, Interim Ratios 33
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 35
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 36
The Medicines Company, Recent Deals Summary 37
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56



List of Figures
The Medicines Company, Pipeline Products by Therapy Area 10
The Medicines Company, Pipeline Products by Development Phase 11
The Medicines Company, Performance Chart (2010 – 2014) 32
The Medicines Company, Ratio Charts 34
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 35
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 36

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.